Imara M&A

Our Strategy and Initial Positioning in an Evolving CML Market Treatment Paradigm 1L (50%) 2L (30%) 3L+ (20%) T3151 1st Gen TKI Imatinib 28% MMR 2nd Gen TKIS ~35% MMR 2nd Gen TKIS Nilotinib, Dasatinib, Bosutinib ~45% MMR 3rd Gen TKI Ponatinib 58% MMR 2nd Gen TKIs ~20-25% MMR 2nd 3rd & 4th Gen TKIs Bosutinib Ponatinib Asciminib ~20% MMR 35% MMR ~33% MMR 4th Gen TKI High Dose Asciminib 58% MMR** 2nd Gen TKIs = Nilotinib, Dasatinib, Bosutinib. MMR = Major Molecular Response at ~12 months. *Depending on patient population ELVN-001 30-40%+ MMR Target* ELVN-001 >50% MMR Target Market Insights ~50% of patients start on 2nd Gen TKIS, driven by faster & deeper molecular responses Further improvement in efficacy may still allow for new entrants in 1L setting HCPs consistently express high interest in prescribing novel agents with improved safety/tolerability and efficacy in 2L+ Asciminib has the potential to become the preferred option in earlier lines of therapy HCPs report up to ~25% of patients end up back on imatinib in 3L+ setting Potentially more tolerable choice for T3151 patients and has the potential to displace ponatinib High dose asciminib is now an option in the US, but risks remain **Ponatinib-naïve patients (n = 21). References HCP Qualitative & Quantitative Interviews (ClearView); Gleevec® (imatinib) USPI; Icsluig (ponatinib) USPI; Sprycel® (dasatinib) USPI; Tasigna® (nilotinib) USPI; Bosulif® (bosutinib) USPI; Cortes JE et al. Blood. 2020;136(Supplement1):47-50; Hochhaus et al. ASH 2020. Market Size (US) ~30K+ O ~18K+ O ~12K+ < $500M USD оо ~2K+ > $2B USD 24

View entire presentation